Insmed (INSM) Cash & Equivalents (2010 - 2026)

Insmed's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $582.2 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 44.38% year-over-year to $582.2 million; the TTM figure through Mar 2026 stood at $582.2 million (up 44.38% YoY), while the FY2025 annual figure was $510.4 million, down 8.03% from the prior year.
• Cash & Equivalents was $582.2 million for Q1 2026 at Insmed, up from $510.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.3 billion in Q2 2025 to a low of $334.8 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $643.9 million across 5 years, with a median of $515.7 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents slumped 55.18% in 2022, then jumped 103.43% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $1.1 billion in 2022, then tumbled by 55.09% to $482.4 million in 2023, then climbed by 15.06% to $555.0 million in 2024, then dropped by 8.03% to $510.4 million in 2025, then grew by 14.06% to $582.2 million in 2026.
• The last three Cash & Equivalents figures came in at $582.2 million (Q1 2026), $510.4 million (Q4 2025), and $334.8 million (Q3 2025), per Business Quant data.